Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 6/20 | 0.47 |
| ▸ | CASP2 | P42575 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22845579 | 0.92 | CASP2 (0.58) | EPHX1CASP2MEN1KMT2AFAAH | |
| SCHEMBL25443809 | 0.90 | KMT2A (0.44) | EPHX1CASP2MEN1KMT2AMAPK1 | |
| SCHEMBL25443810 | 0.90 | KMT2A (0.50) | EPHX1CASP2MEN1KMT2AFAAH | |
| SCHEMBL18736128 | 0.88 | MCL1 (0.45) | EPHX1CASP2MEN1KMT2AFAAH | |
| SCHEMBL16924437 | 0.86 | CASP2 (0.46) | EPHX1CASP2MEN1KMT2AFAAH | |
| SCHEMBL15980869 | 0.85 | ALDH1A1 (0.46) | EPHX1CASP2MEN1KMT2A | |
| SCHEMBL24330011 | 0.82 | KMT2A (0.39) | EPHX1CASP2MEN1KMT2ACNR1 | |
| SCHEMBL15980868 | 0.81 | ALDH1A1 (0.43) | EPHX1MEN1KMT2A | |
| SCHEMBL22306106 | 0.81 | ALDH1A1 (0.42) | EPHX1CASP2MEN1KMT2AFAAH | |
| SCHEMBL25443800 | 0.81 | KMT2A (0.42) | EPHX1CASP2MEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673902-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | C4 THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| EP-3432934-B1 | PRODRUGS OF CYTOTOXIC AGENTS WITH ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma AG (DE) | 2022-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673902-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | EGFR, ERBB2, ERBB3 | EPHX1 3266/4885CASP2 2872/4885MEN1 3601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.